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Effects in the Mouse and Rat
of Prenatal Exposure to Arsenic
by R. D. Hood,* G. T. Thacker,*
and B. L. Patterson*
Initial experiments involving mouse development employed single IP injections of 45 mg/kg sodium
arsenate on one ofdays 6-12 ofgestation and produced a spectrum ofdevelopmental defects. Embryotox-
icity was indicated by high prenatal mortality and decreased fetal weights. A chelating agent,
2,3-dimercaptopropanol (BAL), was then employed in an attempt to alleviate the adverse effects of
prenatal arsenate. BAL was administered 4 hr before, concurrently with, or 4 hr after arsenate. All BAL
treatments diminished arsenate-induced gross malformations and growth retardation; the concurrent
treatment alleviated skeletal malformation. Injection of rats IP with arsenate has also been reported to
result in teratogenicity, including renal agenesis. Further reports indicated that 40 mg/kg arsenate ad-
ministered to mice by gavage on days 9-11 increased prenatal mortality, reduced fetal weights, and was
associated with minor malformations. According to our recent work, however, single oral doses of
arsenate must be around 120 mg/kg to cause prenatal toxicity. Multiple doses of 60 mg/kg on 3 days had
little effect. Sodium arsenite has also been found to be fetotoxic and teratogenic. Such effects were seen at
IP doses of 10-12 mg/kg.
Introduction
Although both man and domestic animals may be
exposed to a variety of arsenic compounds, only a
few such compounds have been investigated with
regard to possible prenatal effects. The initial work
describing embryotoxic and teratogenic effects was
done with chicken embryos by Ancel (1), who used
disodium methylarsenate, and by Ridgeway and
Karnofsky (2), who tested various arsenic salts.
Most subsequent reports have dealt with effects of
arsenic in the hamster, as discussed by Ferm at this
conference (3), and in the mouse and rat, which are
the subject of the balance of this report.
Materials and Methods
For all experiments done in our laboratory,
random-bred albino Swiss-Webster mice of the
CD-1 strain were obtained from Charles River
Mouse Farms and maintained on an ad libitum diet
of Wayne Lab Blox. The day on which a vaginal
plug was found was considered day of gestation.
Arsenic treatments consisted of intraperitoneal in-
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jection or gastric intubation on the gestation day
indicated. Distilled water was used as the solvent
for dibasic sodium arsenate (Na2HAsO4 7H20) or
for sodium arsenite (NaAsO2). One experiment
also involved BAL (British antilewisite or 2,
3-dimercaptopropanol). This chelating agent was
disolved in corn oil and injected subcutaneously in
the nape of the neck. A 50 mg/kg dose of BAL was
administered on gestation day 9, either 4 hr before
(B/A), currently with (A + B), or 4 hr after (A/B)
40 mg/kg arsenate. All mated females were sac-
rificed on gestation day 18. Observations were then
made ofprenatal mortality, fetal malformations and
fetal weights. One third of each litter was cleared
and stained for skeletal observations (4).
Results and Discussion
Our initial work with arsenic (5) involved IP in-
jection ofmice with 25 or 45 mg/kg sodium arsenate
on one of gestation days 6-12. Treatment at the
lower dose level had no discernible effect, but the
high dose caused increased prenatal mortality, de-
creased fetal weights, and a spectrum of gross and
skeletal abnormalities (Table 1). Some of the major
defects observed and their relative frequencies are
listed in Table 2. Such results are indicative of a
August 1977 219Table 1. Effects of sodium arsenate on fetal development in mice:
single IP injections on one of days 6-12 of gestation."
Day of
treatment"
6
7
8
9
10
I 1
12
Control"
No.
pregnant
10
8
11
8
10
10
8
37
Dead or
resorbed,
51
37
56
60
51
69
78
4
Fetal
weight,
g + SE
0.88 + 0.02
0.67 0.03
0.87 + 0.02
0.61 0.03
0.79 + 0.03
0.94 0.03
1.05 0.02
1.05 0.01
Grossly
malformed,
2
34
36
63
26
8
0
l
"Adapted from Hood and Bishop (5).
"Pregnant females received 45 mg/kg sodium arsenate.
"Killed on day 18 ofgestation. Treatment on days 6-11 resulted
in decreased fetal weights when compared with controls
() < 0.05).
"Control mice were injected with distilled H20 on one of ges-
tation days 6-12.
general rather than a specifically acting teratogen,
as the anomalies seen involve a wide variety of de-
velopmental defects.
Frequent exencephalies and eye and rib malfor-
mations similar to those in the mouse have also
been seen in the hamster (6), but in the rat, accord-
ing to Beaudoin (7), arsenate produced a prepon-
derance ofskeletal defects along with renal agenesis
and anophthalmia, and only a relative few ex-
encephalies.
An additional study (8) was done with arsenate to
determine if the chelating agent, BAL, could pro-
tect against the prenatal effects of arsenate. As can
be seen in Table 3, results of arsenate treatment
alone were similar to those previously discussed
(5). BAL alone had no significant adverse effects,
although at the much higher dose of 1200 mg/kg,
BAL has been reported (9) to be teratogenic in
mice. In all cases, however, BAL treatment di-
minished the incidence of arsenate-induced gross
malformations and growth retardation. The concur-
rent treatment (A + B) also alleviated the skeletal
malformations associated with arsenate treatment,
while the other two treatments decreased the sever-
ity (though not the incidence) of such defects. It is
possible that the BAL was acting to increase the
rate ofarsenic excretion and thus reduce embryonic
exposure. The two sulfhydryl groups of the BAL
molecule form a stable ring with arsenite ions, while
the hydroxyl group makes the complex water solu-
ble and excretable in the urine. Thus, if there is an
Table 2. Sodium arsenate-induced fetal anomalies in mice: day of treatment versus response.'
Affected animals with treatment of various gestation periods
Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12
Anomaly N" % N % N % N % N % N % N %
Exencephaly 0/56 0 2/62 3 20/64 31 25/46 54 0/56 0 0/37 0 0/19 0
Shortened jaws 0/56 0 3/62 5 8/64 12 21/46 46 1/56 2 0/37 0 0/19 0
Anophthalmia 0/56 0 1/62 2 7/64 11 4/46 9 0/56 0 0/37 0 0/19 0
Open eye 3/56 5 12/62 19 9/64 14 9/46 20 1/56 2 0/37 0 0/19 0
Umbilical hernia 0/56 0 11/62 18 0/64 0 4/46 9 0/56 0 0/37 0 0/19 0
Malformed limbs 0/56 0 0/62 0 0/64 0 1/46 2 4/56 7 1/37 3 0/19 0
Missing or short tail 0/56 0 0/62 0 0/64 0 3/46 7 0/56 16 1/37 3 0/19 0
Twisted tail 1/56 2 0/62 0 0/64 0 1/46 2 5/56 9 1/37 3 0/19 0
Malformed ribs 0/17 0 0/17 0 5/18 28 11/11 100 0/15 0 0/12 0 0/ 70
Fused vertebrae 0/17 0 0/17 0 0/18 0 11/11 9 11/15 73 0/12 0 0/ 7 0
"Adapted from Hood and Bishop (5).
"Values (N) represent the number of affected animals/total number of fetuses examined.
Table 3. Effects of BAL on arsenate-induced fetal death and malformation in mice."
No. of Dead or Grossly
pregnant resorbed Fetal malformed Skeletal
Treatment mice fetuses,% weight, g + SE fetuses, % malformations, %
A 16 29' 0.78 + 0.01 54 77.7c
B 15 9".' 0.96 ± 0.02-"" 0"1 O.Od
B/A 15 19'. 0.92 ± 0.01" 17' 69.6c
A+B 18 14c- 0.93 ± 0.01" 10 0.0
A/B 15 27' 0.95 ± 0.02-(" 9C 47.8c
+ Control 15 9d.f' 0.95 ± 0.02'.(I"0 0.0"
- Control 12 5" 1.01 ± 0.0°I 0"( °°
"Adapted from Hood and Pike (8).
"For treatments, see materials and methods section.
(""fValues in a category sharing the same superscript were not significantly different (p < 0.05) according to the
Newman-Keuls test.
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tween arsenate and arsenite, the arsenite could be
continually removed as it is produced, having the
effect ofdecreasing the arsenic levels present in the
system.
A study involving the IP injection of sodium
arsenate in pregnant rats has been reported by
Beaudoin (7). Treatment ofWistar rats on one ofges-
tation days 8-13 with a dose of 50 mg/kg invariably
resulted in embryonic mortality. A dose of 20, 30,
or 40 mg/kg caused increased mortality as well as
developmental defects. Burk (10), from the same
laboratory, reported on the apparent causation of
the urogenital agenesis seen by Beaudoin. She
noted a failure of the mesonephric duct to connect
with the cloaca, as well as degeneration of the
metanephrogenic blastema.
In yet another study involving the rat, Kimmel
and Fowler (personal communication) found no ad-
verse effects on development following administra-
tion of 30 or 90 ppm sodium arsenate or arsenite to
the dams in the drinking water throughout preg-
nancy. The dams were killed and examinations
made on gestation day 21.
Additional preliminary work in our laboratory
has involved a comparison ofthe developmental ef-
fects of IP versus PO sodium arsenate in mice. Our
initial results indicate that single doses of at least
120 mg/kg PO must be used to obtain adverse pre-
natal effects. Typical results for treatment on day 9
or 10 are shown in Table 4, in comparison with a
similar group treated with 40 mg/kg IP. Maternal
death rate was similar for both treatments, indicat-
ing similar levels oftoxicity to the dam. Administra-
tion ofarsenate IP had a considerably greater effect
Table 4. Comparison of the prenatal effects of oral (PO) and
intraperitoneal (IP) sodium arsenate in mice.
Treatment" No. of Dead or Fetal Grossly
Dose, pregnant resorbed weight, malformed
Day mg/kg Mode miceb fetuses, % g ± SD fetuses, %
9 40 IP 10(4) 59 0.80 ± 0.13 34
120 PO 9(2) 17 0.94 ± 0.07 1
10 40 IP 10(1) 55 0.82 ± 0.13 15
120 PO 16(2) 26 0.86 ± 0.14 3
None 9(0) 12 1.02±0.11 0
"Single dose on gestation day indicated.
bNumbers in parentheses indicate maternal deaths.
on prenatal mortality than did PO arsenate, even
though the dose was only one third as great. The IP
arsenate also decreased fetal weights in comparison
with untreated controls, while PO treatment had
this effect only when given on day 10. The signifi-
cant rate offetal malformation associated with the 40
mg/kg IP treatment is in agreement with our previ-
oLIs observations (8). A much lower level of mal-
formation, however, was seen in the orally treated
groups.
OUI- results with orally administered sodium
arsenate are in apparent conflict with those of Mat-
sumoto (ii), who treated pregnant ICR mice on
days 9, 10, and II with 10, 20, or 40 mg/kg sodium
arsenate and examined them on day 18. He re-
ported increased prenatal mortality and decreased
fetal weights in the high dose group. In the groups
given the 10 or 40 mg/kg doses, a low rate of mal-
formations was also seen (6 and 4%, respectively).
Since the number oflitters involved was not stated,
it is difficult to assess the significance of
Matsumoto's findings.
Although arsenite is considerably more toxic
than is arsenate, it has received much less attention
from teratologists. We treated mice in iuter(o with IP
injections at dose levels of 10 or 12 mg/kg on one of
days 7-12 of pregnancy (12). Arsenite treatment re-
sulted in relatively high prenatal mortality, as well
as some maternal deaths (Table 5). Treatment on
days 8, 9, or 10 induced both gross and skeletal
malformations partially similar to but less numerous
than those caused by comparably toxic levels of
arsenate. Fetal wastage caused by exposure to
arsenite was increased in comparison with the level
previously seen (5) due to arsenate.
Table 5. Effects of sodium arsenite on fetal development in mice:
Single IP injections on one of days 7-12 of gestation."
Treatment No. of Dead or Grossly T t No. of resorbed Fetal malformed
Dose, pregnant fetuses, weights, fetuses,
Day mg/kg miceb % g + SE %
7 10 6 51' 1.02 ± 0.02 0
12 7 35e 0.91 + 0.02e 2
8 10 6(1) 49c 0.81 ± 0.03' 8
12 8(1) 92' 0.78 + 0.04c 1
9 10 9 20c 0.96 ± 0.01 14'
12 8 78c 0.92 ± 0.04c 27'
10 10 9(1) 88e 0.95 ± 0.02 8
12 6(1) 85c 0.57 ± 0.03c 36'
11 10 9 59' 0.95 0.01 0
12 6(4) 100'C
12 10 6(l) 75e 1.05 ± 0.03 0
12 6(4) 100 -
Control" 36 2 1.05 ± 0.01 0
"Adapted from Hood (12).
"Numbers in parentheses indicate maternal deaths.
'Significantly different from the controls (p < 0.05).
"Controls injected with distilled H2O on one ofgestations days
7-12.
According to the previously discussed results and
uinpublished data from our laboratory, it appears
likely that acute high dose exposure to arsenate is
relatively more hazardous to developing mammals
than is chronic exposure to only slightly lower daily
August 1977 221doses. If this proves to be the case, the most proba-
ble cause lies in the pharmacokinetics involved. Al-
though the pharmacokinetic aspect of the prenatal
effects ofarsenic exposure is yet to be investigated,
it promises to provide interesting answers to the
questions posed by differences in effects associated
with different routes and modes of exposure.
Another aspect of the problem involves the basic
cause for the apparent differences in effect between
arsenate and arsenite with regard to malformation
versus prenatal mortality. This difference would
presumably be due to differing mechanisms of ac-
tion (13), but pharmacokinetics may play a role here
also. Possible postnatal effects of prenatal arsenic
exposure are completely unknown. Answers to the
problems thus posed would provide an additional
basis for assessment of the potential influence of
arsenic on human development.
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